chevron_leftBack
As of 24 April 2025, Gujarat Themis Biosyn Ltd. has a market cap of $391.2M USD, ranking #13364 globally and #863 in India. It ranks #1318 in the Healthcare sector, and #321 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$391.2MUSD
33.38B INR
Enterprise Value
$388.71MUSD
33.23B INR
Revenue (TTM)
$18.17MUSD
1.55B INR
EBITDA (TTM)
$8.36MUSD
714.66M INR
Net Income (TTM)
$6.17MUSD
526.59M INR
EBITDA Margin
46%
Profit Margin
34%
PE Ratio
63.4
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Tapas Guhathakurata
open_in_new
Employees
159
Founded
1981
Website
gtbl.in
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.2% | 20% | 24% | -2.6% | 1% | -18% |
Upcoming Earnings
Earnings Date
Tue, May 13
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GUJTHEM
Gujarat Themis Biosyn Ltd
ISIN: INE942C01045
Shares Out.:
Shares Outstanding:
108.965M1
Shares Float:
30.813M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
315.45 INR | |
|
506879
(GUJTHEM)
Gujarat Themis Biosyn Ltd
ISIN: INE942C01045
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
304.80 INR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Gujarat Themis Biosyn Ltd.
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
